AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 NOV 4 - (NewsRx.com & NewsRx.net) -- Serono (virt-xSEO and NYSE: SRA) announced that the U.S. Food and Drug Administration (FDA) has approved Luveris (lutropin alfa for injection) for concomitant use with Gonal-f (follitropin alfa for injection) for stimulation of follicular development in infertile hypogonadotropic hypogonadal (HH) women with profound LH deficiency (LH
HH is a rare endocrine deficiency. Women with HH are unable to produce the hormones needed for full development of follicles in the ovaries, ovulation, and growth of the lining of the uterus sufficient to support implantation of a fertilized egg and early pregnancy.
Luveris is the first and only approved recombinant human form of luteinizing hormone (LH), a naturally-occurring fertility hormone. The Luveris approval makes Serono the only company to offer three recombinant fertility hormones, part of its long-term global strategy to develop a 100% recombinant human gonadotropin portfolio. By the end of 2004, Serono will complete a ...
Source: HighBeam Research, Concomitant use of Luveris, Gonal ok'd for hypogonadotropic...